References
- MacKay D. Hemorrhoids and varicose veins: a review of treatment options. Altern Med Rev 2001;6:120–40
- Johanson JF, Sonnenberg A. The prevalence of hemorrhoids and chronic constipation. An epidemiologic study. Gastroenterology 1990;98:380–6
- Abramowitz L, Godeberge P, Staumont G, Soudan D; Société Nationale Française de Colo-Proctologie (SNFCP). Clinical practice guidelines for the treatment of hemorrhoidal disease. Gastroenterol Clin Biol 2001;25:674–702
- Sardinha TC, Corman ML. Hemorrhoids. Surg Clin North Am 2002;82:1153–67
- Vanheuverzwyn R, Colin JF, Van Wymersch T, et al. Hemorrhoids review. Acta Gastroenterol Belg 1995;58:452–64 [article in French]
- Johanson JF. Evidence-based approach to the treatment of hemorrhoidal disease. Evidence-Based Gastroenterol 2002;3: 26–31
- Godeberge P. Daflon 500 mg in the treatment of hemorrhoidal disease: a demonstrated efficacy in comparison with placebo. Angiology 1994;45:574–8
- Madoff RD, Fleshman JW; Clinical Practice Committee, American Gastroenterological Association. American Gastroenterological Association technical review on the diagnosis and treatment of hemorrhoids. Gastroenterology 2004;1126: 1463–73
- Godeberge P. Role of the venous component in the development of hemorrhoidal disease: pathophysiological insights and therapeutic implications. Medicographia 2004;26:178–81
- Behar A, Lagrue G, Cohen-Boulakia F, Baillet J. Capillary filtration in idiopathic cyclic edema-effects of Daflon 500 mg. Nuklearmedizin 1988;27: 105–7
- Galley P, Thiollet M. A double-blind, placebo-controlled trial of a new veno-active flavonoid fraction (S 5682) in the treatment of symptomatic capillary fragility. Int Angiol 1993;12:69–72
- Cesarone MR, Laurora G, De Sanctis MT, Belcaro G. Capillary filtration and ankle edema in patients with venous hypertension: effects of Daflon. Angiology 1993;44:57–61
- Lyseng-Williamson KA, Perry CM. Micronised purified flavonoid fraction: a review of its use in chronic venous insufficiency, venous ulcers and haemorrhoids. Drugs 2003;63:71–100
- Bouskela E, Donyo KA, Verbeuren TJ. Effects of Daflon 500 mg on increased microvascular permeability in normal hamsters. Int J Microcirc Clin Exp. 1995;15(Suppl 1):S22–S26
- Coleridge-Smith P. Neutrophil activation and mediators of inflammation in chronic venous insufficiency. J Vasc Res 1999;36(Suppl 1):S24–S36
- Korthuis RJ, Gute DC. Postischemic leukocyte/endothelial cell interactions and microvascular barrier dysfunction in skeletal muscle: cellular mechanisms and effect of Daflon 500 mg. Int J Microcirc 1997;17(Suppl 1):S11–S17
- Schmid-Schönbein G. Inflammation and the pathophysiology of chronic venous insufficiency. Phlebolymphology 2003;39:95–104
- Cospite M. Double-blind, placebo-controlled evaluation of clinical activity and safety of Daflon 500 mg in the treatment of acute hemorrhoids. Angiology 1994;45:566–73
- Misra MC, Parshad R. Randomized clinical trial of micronized flavonoids in the early control of bleeding due to acute internal haemorrhoids. Br J Surg 2000;87:868–72
- Menyhei G, Acsady G, Hetenyi A, et al. Chronobiology and clinical activity of Daflon 500 mg in chronic venous insufficiency. Phlebology 1994;9(Suppl 1):S15–S18
- Meyer OC. Safety and security of Daflon 500 mg in venous insufficiency and in hemorrhoidal disease. Angiology 1994;45:579–84
- Anon. Stedman’s medical dictionary, 27th ed. Baltimore (MD): Lippincott Williams and Wilkins; 2000